Clinical Trial Update: Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for carfilzomib, rituximab and dexamethasone in Waldenström's macroglobulinemia has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2017-03-21